Amedisys (AMED) Gets a Hold Rating from Stephens


In a report released today, Dana Hambly from Stephens reiterated a Hold rating on Amedisys (NASDAQ: AMED), with a price target of $110. The company’s shares opened today at $106.01, close to its 52-week high of $108.92.

According to TipRanks.com, Hambly is a 4-star analyst with an average return of 9.4% and a 62.7% success rate. Hambly covers the Services sector, focusing on stocks such as Encompass Health Corporation, Capital Senior Living, and Addus Homecare Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amedisys with a $101.50 average price target, which is a -4.3% downside from current levels. In a report released yesterday, Robert W. Baird also reiterated a Hold rating on the stock with a $105 price target.

.

See today’s analyst top recommended stocks >>

Amedisys’ market cap is currently $3.3B and has a P/E ratio of 49.91. The company has a Price to Book ratio of 8.09.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts